Recent Finacing
Recent Raise
ETERN Therapeutics develops a protein LLPS-based small-molecule platform to modulate traditionally "undruggable" targets (e.g., transcription factors, phosphatases), advancing multiple pipelines including clinical-stage SHP2 inhibitor ET0038.
